Key Takeaways
- Year-Long Surge: Illumina stock has climbed 133% over the past year, closing at $240 on September 18, 2026, up from roughly $103 twelve months earlier.
- Street Split: Illumina stock carries 7 buy ratings, 4 outperforms, 6 holds, 3 underperforms and 1 sell, and the $203 mean target now sits 15% below where shares trade, a reversal from a year ago when the target sat above the price.
- Model Gap: TIKR’s mid case model values Illumina at $270 by December 2030.
- Insider Cashout: Director Keith Meister has disposed of more than $255M in shares since early August, even as the rally accelerated.
Why Illumina Stock’s 133% Run Has Outpaced Wall Street’s Own Targets
Illumina (ILMN) stock has climbed 133% over the past year, closing at $240 on September 18, 2026, a run that has erased two years of underperformance tied to the GRAIL divestiture and Chinese sales restrictions.
The turn traces to a string of earnings beats that kept building on each other. Illumina posted adjusted EPS of $1.31 in the second quarter of 2026, ahead of the $1.23 Wall Street expected, on revenue of $1.16 billion, up 9.5% year over year. That followed a Q1 beat of $1.15 versus a $1.05 estimate and a Q4 2025 beat of $1.35 versus $1.23. Management responded by raising full-year guidance to $5.30 to $5.40 in adjusted EPS and lifting its organic revenue growth outlook to above 5%, up from a prior range of 2% to 4%.
Behind those numbers sits a bet that clinical sequencing demand keeps compounding rather than fading. CEO Jacob Thaysen addressed that skepticism directly on the Q2 2026 earnings call: “Talking about the clinical cliff, I agree, it’s not a cliff. It’s a wave, and we are surfing it as you are saying.” Roughly 78% of clinical sequencing volume now runs on the NovaSeq X platform, and management expects that to reach 80% to 85% by year end, a conversion that keeps feeding consumables revenue long after the instruments ship.
Index mechanics added their own push. Illumina joined the S&P 500 effective September 21, migrating up from the S&P MidCap 400, which forced passive funds to buy shares regardless of valuation. Argus Research raised its price target to $235 from $180 around the same stretch, one of several upward revisions that chased the stock rather than led it. Illumina stock’s rally looks less like a single catalyst and more like fundamentals, index flows and a re-rating Street feeding each other in sequence.
Insider Selling Complicates Illumina Stock’s Record Run
That same rally has given company insiders an exit. Director Keith Meister disposed of $76.95 million in shares in late August and another $30.51 million in early September, on top of $148.86 million sold in early August, putting his disposals above $255 million in roughly six weeks. None of those sales change the earnings trajectory, but they mark a steady source of supply landing on top of the S&P 500-driven demand, a tension worth watching as the stock’s momentum matures.
Illumina Stock’s Mean Target Now Trails the Price for the First Time in a Year
Illumina stock now carries 7 buy ratings, 4 outperforms, 6 holds, 3 underperforms and 1 sell. Separately, 20 analysts currently publish a price target, and their mean sits at $203, putting the stock 15% above where the Street, on average, thinks it belongs.
That is a reversal from where things stood a year ago. Back on June 29, 2025, the mean target of $109 sat 15% above a $95 close. Analysts have since raised that mean target nearly every quarter, to $125, then $136, then $152, then $203 today, but the price outran each revision, climbing from $95 to $240 over the same stretch. Coverage has also thinned, falling from 23 analysts publishing targets a year ago to 20 now, even as the stock became one of the market’s sharpest movers.
The Street has been chasing this stock upward the entire way, and for the first time in a year, the chase has fallen behind.
TIKR Values Illumina Stock at $270 by 2030, a Fraction of the Recent Rally
TIKR’s mid case model values Illumina at $270 by December 2030, implying a 13% total return from the current price of $240, or 3% annualized over the next 4.3 years.
That annualized pace lands well below the returns life-science tools investors have collected over the past year, positioning Illumina stock as a far slower compounder from here than its recent chart suggests.
The gap matches what the Street’s own numbers already show: with the mean target sitting below the current price and coverage thinning rather than expanding, the easy re-rating from index inclusion and consecutive beats looks largely priced in, leaving continued clinical conversion, not another multiple expansion, as the main lever left for further gains.
Should You Invest in Illumina, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Illumina, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Illumina, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ILMN stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
